Suraj Sakaria, CFA

Investor for 10+ yrs. Still a student. Hunting for moats, management, & magic in MicroCap.

SEBI Registered Research Analyst (INH000027885)

[Suraj Sakaria, CFA @suraj_earlyedge]

Most microcap investors lose money.
Not because the story was wrong...
But because they ignored the red flags.

After analyzing 500+ stocks, I built a 20-point Excel checklist that reveals shady governance, financial tricks & red flags — in just 2 hours.

I walk through it LIVE with a real example (Infollion)
Watch the breakdown - https://t.co/EvRANl82G9

This free tool can save you months of wasted research.
Try it before your next investment.

[Suraj Sakaria, CFA @suraj_earlyedge]

RBL Banks management repeatedly spoke about reducing funding costs, building NRI deposits, leveraging trade corridors and improving ROA.

Those are the structural changes that could drive a long-term rerating.

Not a reco.

#RBLBank

[Suraj Sakaria, CFA @suraj_earlyedge]

A few weeks ago, I wrote that Ather looked expensive on current earnings but more reasonable on forward basis.

Today's capital raise reinforces that people who know the business best are still willing to buy at ₹1,230–1,260/share.

That's a signal worth watching.

#ather

[Suraj Sakaria, CFA @suraj_earlyedge]

@rhjain87 So rather than giving name let me give my process.

So my process starts with PEAD to narrow the universe and then fundamental research to see if the earnings surprise is sustainable.

I've covered the complete process here: https://t.co/RMvK6IfTJV

[Suraj Sakaria, CFA @suraj_earlyedge]

Interesting PEAD case study from Bajaj Consumer.

The numbers looked healthy, but the presentation and management commentary pointed to slowing gross margin expansion.

The market always reprices future expectations rather than current earnings.

#bajajconsumer

[Suraj Sakaria, CFA @suraj_earlyedge]

Worth saving if pharma is part of your investing universe.

Thanks for sharing.

#pharma

[Shiladitya @shiladitya4u]

Pharma Cheat Sheet

As you all know, I am heavily invested in Pharma - it is by far my highest allocation, around 35-40%

For someone like me, with no background of pharma, it is extremely difficult to understand the basics and all the jargons related to different types of molecules, regulatory approvals etc.

So, I created this sheet sheet working with GPT, keeping an investor perspective in mind.
Hope it helps.. you can keep it as a reference.
I don't claim any accuracy, as I am not an expert.
Let's keep learning and sharing 🙂🙂

[Suraj Sakaria, CFA @suraj_earlyedge]

One of the ways I identify potential multibaggers is through PEAD (Post-Earnings Announcement Drift.)

I have pinned down the 9-step PEAD framework I use each results season, with Balaji Amines as a example.

https://t.co/GyASuUEeOs

#PEAD #BalajiAmines

[Suraj Sakaria, CFA @suraj_earlyedge]

@KaustubhYeole Thank you so much Kaustubh, really appreciate you taking the time to watch it and share this.

Glad you found the ICE Make presentation useful.

[Suraj Sakaria, CFA @suraj_earlyedge]

Creative Graphics

Can a niche packaging company use a large pharma expansion to create its next growth phase?

This session deep dives at Creative Graphics’ established packaging business and its move into pharma packaging.

Not a reco.

https://t.co/TexRCVES4Q

#creativegraphic

[Suraj Sakaria, CFA @suraj_earlyedge]

Every results season, hundreds of companies report strong earnings.

But only a handful go on to become multibaggers.

In this webinar, I share the framework I use to identify them before the market fully catches on.

https://t.co/WZgWtqAGGz

#Investing #PEAD

[Suraj Sakaria, CFA @suraj_earlyedge]

Honasa is paying ₹135 Cr for Fluence.

Fluence has grown revenue from ₹32 Cr to ₹37 Cr over the last three years.

Looks like they're buying patented IP, doctor trust, and distribution.

The valuation only makes sense if management can unlock value.

#Honasa

[Suraj Sakaria, CFA @suraj_earlyedge]

Had been trimming MTAR Tech over the last few days.

Not because I predicted today's news, but because the position had become large and the risk-reward had changed.

The best portfolio decisions are often made before the reason becomes obvious.

Not a reco.

#mtar

[Suraj Sakaria, CFA @suraj_earlyedge]

This is only Google's data. → token volumes have increased roughly 7x YoY.

Now imagine what the combined demand from Google, Microsoft, Meta, Amazon and OpenAI looks like.

#ai

[Suraj Sakaria, CFA @suraj_earlyedge]

Member Deep Dive #2 is now live.

This session was originally recorded in March and focused on the Data Centre ecosystem, along with 10 companies we believe are best positioned.

As always, this is not investment advice.

#datacentre #AIstocks

https://t.co/FCNQxvvOPv

[Suraj Sakaria, CFA @suraj_earlyedge]

@India0Jain Unfortunately I can give any recommendations!

[Suraj Sakaria, CFA @suraj_earlyedge]

One underrated edge in small/microcaps is reading what the parent company communicates globally.

Nitta Gelatin India does not give any PPTs or concalls.

That makes tracking the parent company communication even more important.

Not reco.

#Nittagelatin

[Suraj Sakaria, CFA @suraj_earlyedge]

Over the last few months, we’ve done several deep-dive sessions for our members.

I’ll slowly start sharing them.

First video: Sakar Healthcare and its transition into oncology manufacturing.

Not investment advice.

#SakarHealth #pharma

https://t.co/zZvzd1AIYp

[Suraj Sakaria, CFA @suraj_earlyedge]

Interesting update from Venus Pipes: ₹185 Cr LOI from a data center customer.

An LOI is not a firm order, but it is definitely an interesting optionality worth tracking from an investor’s perspective.

Not a recommendation.

#Venuspipes

[Suraj Sakaria, CFA @suraj_earlyedge]

1 quarter is a headline.

2 quarters can still be transition effects.

3 quarters start building credibility.

Honasa now looks less like a temporary recovery bounce and more like a genuine “3-quarter-rule” case study.

https://t.co/yjFn69zkoO

Not an advice.

#honasa

[Suraj Sakaria, CFA @suraj_earlyedge]

Sterlite Tech:

Promoters bought in the open market around May 7–8.

Two weeks later, STL announced a ~$1.11B (INR 9500 Cr. approx) hyperscaler supply agreement till FY29.

Interesting sequence.

Not an advice, just an observation

#sterlitetech #STL

[Suraj Sakaria, CFA @suraj_earlyedge]

If you think Sterlite Tech is already expensive, see what the promoters are doing.

They bought more shares from the open market on May 7–8.

Interesting timing.

What are they seeing that the market still isn’t?

#Sterlitetech #Sterlite

[Suraj Sakaria, CFA @suraj_earlyedge]

Sansera’s ADS disclosure is significantly more thoughtful than what you typically see in the broader ancillary space.

More importantly, the numbers suggest the transition from a traditional auto ancillary base is real.

Not an advice.

#sansera #sanseraeng